N@N

Market Maker Surveillance Report. PRKR, NAKD, MBRX, EARK, CIIX, KURA, Winning Stocks With Lowest Price Friction For Tuesday, M

March 7, 2017 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 5412 companies with "abnormal" market making, 2004 companies with positive Friction Factors and 4076 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. ParkerVision, Inc. (NASDAQ:PRKR), Naked Brand Group Inc. (NASDAQ:NAKD), Moleculin Biotech Inc. (NASDAQ:MBRX), Ecoark Holdings Inc. (OTC:EARK), Chnieseinvestors.com Inc. (PINK:CIIX), Kura Oncology Inc. (NASDAQ:KURA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  PRKR    $0.430    0.20%     871,200      40.72%    780,174      36.47%    91,026       2,117   
  NAKD    $0.430    0.20%     2,428,931    41.93%    2,427,616    41.91%    1,315        31      
  MBRX    $0.210    0.20%     1,073,203    45.00%    927,500      38.89%    145,703      6,938   
  EARK    $0.850    0.20%     104,484      58.48%    58,481       32.73%    46,003       541     
  CIIX    $0.220    0.17%     128,136      65.38%    67,475       34.43%    60,661       2,757   
  KURA    $2.250    0.31%     89,617       31.73%    74,792       26.48%    14,825       66      

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows PRKR with a dollar gain Tuesday of $0.43000 and a Friction Factor of 2,117 shares. That means that it only took 2,117 more shares of buying than selling to move PRKR higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

ParkerVision, Inc. (NASDAQ:PRKR) - ParkerVision, Inc. designs, develops, and markets proprietary radio frequency (RF) technologies and products for use in wireless communication products and applications in the United States. The company offers technologies for processing RF waveforms in wireless applications. Its technology applies to transmit and receive functions of transmitters, receivers, and transceivers, as well as other related RF communications functions. The transmit portion of the technology, Direct2Power, enables the transformation of a baseband data signal to an RF carrier waveform at the desired power output level in a single unified operation; and the receiver portion of the technology, Direct2Data, enables the direct conversion of an RF carrier to a baseband data signal, as well as enables the direct conversion of a baseband signal to a modulated RF carrier signal. The company also provides engineering consulting and design services to its customers to assist them in developing prototypes and/or products incorporating its technologies. It focuses on incorporating its technologies into various markets that incorporate RF transmitters, receivers, and/or transceivers, including mobile handsets, tablets, femtocells, digital television, machine-to-machine products, RF identification, cable modems, satellite communication, infrastructure, and others. The company s technology is also used to develop and market various RF components products for infrastructure, industrial, and military applications. ParkerVision, Inc. was founded in 1989 and is headquartered in Jacksonville, Florida..

Naked Brand Group Inc. (NASDAQ:NAKD) - NATIONAL AUTO CREDIT INC.

Moleculin Biotech Inc. (NASDAQ:MBRX) - Metabasis Therapeutics, Inc. (Metabasis), incorporated in April 1997, is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for chronic diseases involving pathways in the liver. The Company has four product candidates in clinical trials: Pradefovir, CS-917, MB07133 and MB07803. Pradefovir for the treatment of hepatitis B has completed Phase II clinical trials. CS-917 for the treatment of type 2 diabetes is in Phase II clinical trials. MB07133 for the treatment of primary liver cancer is in a Phase I/II clinical trial. MB07803, also for the treatment of type 2 diabetes, is in a Phase I clinical trial. Metabasis uses its HepDirect technology and other liver-targeting technology in collaboration with Merck & Co. to identify drugs to treat hepatitis C infection. The Company also uses NuMimetic technology in collaboration with Merck to treat metabolic diseases such as type 2 diabetes, hyperlipidemia and non-alcoholic steatohepatitis, by inhibiting cholesterol and lipid production in the liver.

Pradefovir

Pradefovir is an oral product candidate designed using the Company's HepDirect technology. It delivers high concentrations of adefovir to the liver, while limiting the amount of adefovir generated outside of the liver to reduce dose-related toxicities.

CS-917

CS-917, an oral product candidate for type 2 diabetes, inhibits a metabolic pathway in the liver called gluconeogenesis, which is responsible for the excessive production of glucose by patients with type 2 diabetes. The product is being developed in partnership with Daiichi Sankyo Co., Ltd., which has completed a number of Phase I clinical trials of CS-917 in healthy volunteers, as well as Phase I and Phase II clinical trials of CS-917 in type 2 diabetic patients. In February 2006, a Phase IIb clinical trial of CS-917 was initiated by Daiichi Sankyo.

MB07133

MB07133 is an intravenously administered product candidate in a Phase I/II clinical trial designed to evaluate safety and preliminary efficacy in a limited number of patients with primary liver cancer. Using the HepDirect technology, the product targets the active form of araC to the liver while decreasing levels of the active form of the drug in tissues outside of the liver.

MB07803

MB07803 is an oral product candidate for type 2 diabetes that was discovered using Metabasis' NuMimetic technology. Designed to have the same mechanism of action as CS-917, the second-generation drug blocks the gluconeogenesis pathway in the liver by inhibiting FBPase.

MB07811

Metabasis has a clinical development candidate, MB07811, for the treatment of high cholesterol and obesity. MB07811 is designed to act by controlling the expression of certain genes in the liver. The product is undergoing pre-clinical development including scale-up, toxicology (animal studies) and formulations development..

Ecoark Holdings Inc. (OTC:EARK) - EARMARK INC.

Chnieseinvestors.com Inc. (PINK:CIIX) - .

Kura Oncology Inc. (NASDAQ:KURA) - .

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS Friction Factor - Market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements" Naked Shorts (RegSho) - Tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING Earnings - Predicts probability, price move and length of move before and after all US stock earnings reports Seasonality - Predicts probability, price move and length of move based on exact time of year for all US stocks Group Correlation - Tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups SqueezeTrigger - Massive database that tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock. Valuation - Tracks all known valuation models and applies them. GATS - Tracks and quantifies known trading strategies by backtesting, optimizing and running genetic algorithms and neural networks to ascertain best trading strategies. PatternScan - Automates tracking of every technical pattern and predicts next move in stocks. Insider - Tracks insiders trading records and determines trading performance. Trades by higher-level insiders are generally more predictive than trades by lower level insiders Events - Tracks patterns directly correlated to specific events.

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net